Peptide Profile
Melanotan II
What Is Melanotan II?
So what is melanotan 2? Melanotan II (CAS 121062-08-6, molecular formula C₅₀H₆₉N₁₅O₉, molecular weight 1024.18 g/mol) is a cyclic lactam analog of α-MSH, the endogenous hormone that regulates melanin production in the skin. The mt-2 peptide was synthesised by modifying the core 4-10 amino acid sequence of α-MSH (Ac-Nle⁴-Asp⁵-His⁶-D-Phe⁷-Arg⁸-Trp⁹-Lys¹⁰-NH₂) with a lactam bridge between positions 5 and 10 to create a cyclic structure with enhanced stability and potency.[1]
Unlike the linear α-MSH molecule, which is rapidly degraded by peptidases, the cyclic structure of melanotan 2 confers significantly greater resistance to enzymatic breakdown — though its plasma half-life remains relatively short at approximately one hour. The compound is described as “superpotent” relative to α-MSH in melanotropic activity assays, meaning it stimulates melanocyte activity at substantially lower concentrations.[1]
The critical pharmacological distinction is that melanotan II is non-selective across melanocortin receptor subtypes. It activates MC1R (melanogenesis), MC3R and MC4R (sexual function, appetite, energy homeostasis), and MC5R (exocrine gland function). This broad receptor profile is responsible for both its diverse range of researched effects and its significant side effect burden. It was this non-selectivity that ultimately led to the development of PT-141 (bremelanotide), a derivative engineered for greater MC3R/MC4R selectivity without the melanogenic tanning effects.
Compound Profile
Mechanism of Action
Melanotan 2 exerts its effects through activation of four of the five known melanocortin receptor subtypes. Each receptor mediates distinct physiological processes, which explains the compound’s broad and sometimes problematic activity profile:
MC1R — Melanogenesis. MC1R is expressed primarily on epidermal melanocytes. When activated by melanotan II, it triggers a cAMP-dependent signalling cascade that upregulates tyrosinase activity and shifts melanin production from the lighter pheomelanin toward the darker eumelanin. This is the mechanism underlying the compound’s tanning effect — increased eumelanin synthesis produces visible skin darkening, often described in research subjects after only a few administrations.[1][6] This mechanism is distinct from UV-induced tanning in that it can occur independently of ultraviolet light exposure, though it works synergistically with UV.
MC3R and MC4R — Sexual Function and Appetite. These centrally-expressed receptors in the hypothalamus mediate the compound’s effects on sexual arousal and appetite. MC4R activation in the paraventricular nucleus has been shown to initiate erectile responses in male subjects and increase sexual desire in both sexes.[2][3] The same MC4R pathway is involved in central appetite regulation — activation of hypothalamic MC4R suppresses food intake, contributing to the anorexigenic effects observed during melanotan 2 tanning research.[5] MC3R contributes to both sexual arousal and energy homeostasis, though its specific role remains less well characterised.
MC5R — Exocrine Function. MC5R is expressed in exocrine glands (sebaceous, lacrimal, preputial). Its activation by MT-II may influence sebum production and exocrine secretion, though this pathway has received the least research attention in the context of melanotan II specifically.
The non-selective activation of all these receptors simultaneously is the core issue with melanotan 2 as a therapeutic candidate. The desired melanogenic effect via MC1R cannot be separated from the centrally-mediated sexual, appetite, and autonomic effects via MC3R/MC4R, or the nausea and fatigue that appear to be dose-dependent class effects.[1][4]
Tanning & Melanogenesis Research
The original research rationale for melanotan 2 was as a sunless tanning agent — specifically, a compound that could stimulate protective eumelanin production to reduce skin cancer risk in fair-skinned populations. The pivotal early work was conducted at the University of Arizona in the mid-1990s.
In the first published Phase I trial (Dorr et al., 1996), three male subjects received subcutaneous melanotan injection at escalating doses of 0.01-0.03 mg/kg on alternating days for two weeks. Even at these low doses, two of three subjects showed measurable increases in facial and upper body pigmentation, as confirmed by quantitative reflectance spectrophotometry, persisting for at least one week after dosing ended.[1] This was significant because it demonstrated that melanogenesis could be pharmacologically induced without UV exposure — a finding that generated substantial interest in the concept of a “tanning peptide.”
Subsequent clinical work confirmed the melanogenic effect. The increased pigmentation observed in melanotan before and after assessments was consistent across skin types, though the magnitude of response varied. Subjects with lighter baseline skin tones (Fitzpatrick I-II) tended to show more dramatic changes.[1][6] However, the effect was not limited to cosmetically desirable uniform darkening. Researchers noted that existing melanocytic naevi (moles) also darkened, and new naevi sometimes appeared — an observation that would later become a significant safety concern.[7][8]
The compound was also investigated in melanotan nasal spray formulations as an alternative to subcutaneous melanotan injection, aiming to improve convenience and compliance. Intranasal administration showed detectable bioavailability, though with lower and more variable absorption compared to subcutaneous delivery. Both routes of administration produced similar patterns of melanogenic response, but the injectable route remained the primary research modality due to more predictable pharmacokinetics.
Despite the demonstrated melanogenic efficacy, clinical development for skin-darkening indications was not pursued to registration due to the compound’s non-selective receptor profile and the associated burden of systemic side effects. The melanogenic pathway was instead pursued through afamelanotide (Melanotan I / Scenesse®), a linear α-MSH analog with greater MC1R selectivity, which ultimately received regulatory approval for erythropoietic protoporphyria.
Sexual Function Research
The discovery that melanotan 2 affected sexual function was accidental — researchers in the original tanning studies observed spontaneous penile erections in male subjects. This observation prompted a dedicated programme of clinical investigation that ultimately produced the most rigorous data available for any Melanotan II indication.
Wessells et al. (1998) conducted a double-blind, placebo-controlled crossover study in 10 men with psychogenic erectile dysfunction (ED). Subcutaneous melanotan injection at 0.025 mg/kg produced clinically apparent erections in 8 of 10 men. Mean duration of tip rigidity above 80% was 38 minutes with MT-II versus 3 minutes with placebo (p=0.0045). Transient nausea, yawning, and decreased appetite were the primary side effects.[3]
A follow-up study by the same group (Wessells et al., 2000) extended these findings to men with organic ED — a more challenging population. In a similar double-blind crossover design, melanotan II initiated subjectively reported erections in 12 of 19 injections versus 1 of 21 placebo doses. Increased sexual desire was reported after 68% of MT-II doses compared to 19% of placebo (p<0.01). However, 4 of 19 injections were associated with severe nausea, highlighting the dose-limiting tolerability issues.[4]
In a broader review, Wessells et al. (2000) concluded that MT-II led to penile erection in 17 of 20 men in the absence of sexual stimulation — a remarkably high response rate. Critically, the erectogenic effect operated centrally, through hypothalamic melanocortin pathways rather than peripheral vasodilation.[5] This was a fundamentally different mechanism from PDE5 inhibitors like sildenafil, and suggested potential for treating desire-related (rather than vascular) sexual dysfunction.
Hadley (2005) reviewed the cumulative evidence and described melanotan II as capable of enhancing sexual function in both males (erectile activity) and females (increased sexual desire and genital arousal), noting that it “works at the level of the brain, thus eliciting a rather natural sexual response.”[2] However, the non-selective receptor profile meant the sexual effects could not be separated from the unwanted tanning, nausea, and autonomic side effects.
This limitation directly motivated the development of PT-141 (bremelanotide) — the active metabolite of MT-II, engineered for selective MC3R/MC4R agonism without MC1R-mediated melanogenesis. PT-141 was subsequently advanced through full clinical development and received FDA approval in 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women. The story of melanotan II’s sexual function research is, in many ways, the story of how PT-141 came to exist.
Appetite & Weight Effects
The anorexigenic (appetite-suppressing) effects of melanotan 2 were observed as side effects in the earliest clinical trials, where subjects consistently reported decreased appetite alongside nausea and other autonomic effects.[1][3] This is mechanistically attributable to MC4R activation in the hypothalamus, specifically in the arcuate nucleus and paraventricular nucleus — the same pathway exploited by endogenous α-MSH as part of the leptin-melanocortin satiety axis.
Preclinical research has extensively characterised MC4R as a central regulator of appetite and energy homeostasis. A systematic review by Fani et al. (2014) positioned MC4R as a key target for obesity pharmacotherapy, noting that loss-of-function MC4R mutations produce severe early-onset obesity in humans.[10] MT-II, as a potent MC4R agonist, produced reliable appetite suppression in animal models — but its non-selective receptor profile made it unsuitable for obesity drug development.
The weight-management effects of melanotan II have not been formally investigated in dedicated human clinical trials. The appetite suppression observed in tanning and sexual function studies was consistent but secondary to the primary endpoints. Compounds with more selective MC4R agonism, including setmelanotide (which targets MC4R specifically for genetic obesity syndromes), have since been developed for this pathway. For readers interested in pharmacological appetite regulation, the GLP-1 receptor agonist class — including semaglutide and tirzepatide — represents the current standard in weight management research.
Side Effects & Safety Concerns
This section requires particular emphasis because melanotan side effects are both frequent and potentially serious. Unlike many research peptides where safety concerns are largely theoretical due to limited human data, Melanotan II has a documented adverse event profile from clinical trials, case reports, and post-marketing surveillance of unregulated use.
Acute Side Effects (dose-dependent, commonly reported):
- Nausea — the most common adverse event, reported at nearly all dose levels. At 0.025 mg/kg, approximately 13% of subjects experienced severe nausea. This appears to be a direct central effect rather than gastrointestinal.[1][4][5]
- Facial flushing — transient vasodilation, typically lasting 30-60 minutes post-administration
- Fatigue and somnolence — reported at higher doses (Grade II at 0.03 mg/kg)[1]
- Yawning and stretching complex — a distinctive autonomic response that often preceded sexual arousal effects[1][3]
- Spontaneous erections — occurring for 1-5 hours post-dose, dose-dependent. While this was the intended therapeutic effect in ED studies, it is an unwanted side effect in tanning contexts and carries risk of priapism.[9]
Dermatological Concerns (significant, potentially dangerous):
- Melanocytic naevi changes — multiple case reports document darkening of existing moles, emergence of new naevi, and dermoscopic changes that can mimic melanoma. Mang et al. (2012) documented sequential dermoscopic changes in a subject using MT-II, finding that naevi changes made it “difficult to differentiate a nevus from a melanoma.”[7]
- Dysplastic naevi — case reports describe the appearance of new dysplastic (atypical) naevi during MT-II use.[6][8]
- Melanoma concerns — Habbema et al. (2017) reviewed multiple cases where melanomas emerged from existing moles either during or shortly after MT-II use. While causal evidence is lacking, the theoretical concern is that stimulating melanocyte proliferation could accelerate pre-existing malignant or pre-malignant changes.[6]
Cardiovascular and Renal Events:
- Renal infarction — Peters et al. (2020) reported a case of renal infarction attributed to MT-II use, noting possible thrombotic pharmacological effects and direct toxic effects on renal parenchyma.[9]
- Priapism — Dreyer et al. (2019) documented a case of acute priapism requiring emergency cavernosal aspiration and phenylephrine injection. The patient had not recovered erectile function at 4-week follow-up.[9]
- Rhabdomyolysis — documented in association with MT-II use[9]
Regulatory Warnings:
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) issued warnings about unlicensed melanotan products in 2008. The Australian Therapeutic Goods Administration (TGA) has repeatedly warned against use. The European Medicines Agency (EMA) has flagged melanotan risks including the danger of contaminated unregulated products. These warnings cite the compound’s unlicensed status, unpredictable purity of internet-sourced products, and the documented adverse event profile as primary concerns.[8]
Any melanotan 2 review that omits these safety concerns is incomplete. The compound carries meaningful risks, particularly with unregulated products of unknown purity, and its development was discontinued specifically because the benefit-risk profile was unfavourable.
Evidence Quality & Limitations
The evidence base for melanotan 2 is limited-moderate by modern clinical standards. The key limitations are:
- Small sample sizes — the Phase I melanogenesis trial included only 3 subjects.[1] The erectile function studies enrolled 10-20 subjects each.[3][4][5] These are pilot-scale studies, not registration-quality trials.
- Discontinued development — no Phase III trials were conducted. The development path was abandoned in favour of more selective derivatives (PT-141, afamelanotide), meaning the full clinical profile was never characterised.
- Unregulated supply concerns — much of the safety data comes from case reports involving internet-sourced products of unknown purity and concentration. Langan et al. (2010) noted that products labelled as melanotan I or II, obtained via the internet, tanning salons, and gyms, may be impure or mislabelled.[8] This complicates adverse event attribution.
- No long-term safety data — clinical exposure was limited to days or weeks. The dermatological concerns (naevi changes, melanoma risk) may require longer observation periods to properly characterise.
- Publication bias — most published clinical data comes from a single research group at the University of Arizona, with limited independent replication.
The strongest evidence exists for the erectogenic effects (double-blind, placebo-controlled crossover designs) and for the melanogenic effects (quantitative reflectance measurements). The weakest evidence concerns long-term safety, particularly the relationship between MC1R stimulation and melanocyte malignancy — a question that may be unanswerable given that formal development was discontinued.
Half-Life & Pharmacokinetics
Melanotan II has a relatively short plasma half-life of approximately 1 hour following subcutaneous administration. This is substantially shorter than many other research peptides — for comparison, PT-141 has a half-life of approximately 2.5 hours, and GLP-1 agonists like semaglutide have half-lives measured in days.
Despite this short half-life, the melanogenic effects of MT-II persist well beyond the plasma clearance period. In the Dorr et al. (1996) Phase I trial, increased pigmentation was measurable one week after dosing ended, suggesting that the downstream melanocyte effects (eumelanin synthesis, melanin deposition in keratinocytes) operate on a much longer timescale than the peptide’s presence in circulation.[1] This is pharmacodynamically consistent — melanin, once synthesised and deposited, persists until the melanin-containing keratinocytes are shed through normal epidermal turnover.
The compound is administered primarily via subcutaneous injection in research settings. Intranasal formulations (melanotan nasal spray) have been investigated and show bioavailability, though with greater inter-subject variability and lower peak plasma levels compared to injection. Oral bioavailability is negligible due to peptide degradation in the gastrointestinal tract.
FAQ
What is melanotan 2 and how does it work?
Melanotan 2 (MT-II, melanotan II) is a synthetic cyclic analog of α-melanocyte-stimulating hormone. It works by activating melanocortin receptors (MC1R, MC3R, MC4R, MC5R) to stimulate melanin production in the skin, influence sexual arousal pathways in the hypothalamus, and suppress appetite through central nervous system signalling. It is a research compound that is not approved for human use by any regulatory agency.
Is melanotan 2 the same as PT-141?
No. PT-141 (bremelanotide) was derived from Melanotan II but is structurally modified for selective MC3R/MC4R activation. PT-141 does not cause skin tanning (no MC1R activity) and has been FDA-approved for hypoactive sexual desire disorder. Melanotan II is non-selective, causes tanning, and was never approved for any indication.
What are the most common melanotan side effects?
The most frequently reported melanotan side effects in clinical trials include nausea (the most common, dose-dependent), facial flushing, fatigue, yawning, spontaneous erections, and decreased appetite. More serious adverse events documented in case reports include changes to melanocytic naevi (moles), priapism, renal infarction, and rhabdomyolysis. The compound carries significant safety concerns, particularly regarding naevi changes and products of unknown purity.
Can melanotan 2 cause melanoma?
This remains an unresolved concern. Multiple case reports have documented melanomas emerging from existing moles during or shortly after melanotan use, and the compound demonstrably stimulates melanocyte proliferation and naevi changes.[6][7] However, direct causal evidence linking MT-II to melanoma induction has not been established. The theoretical mechanism (MC1R-driven melanocyte proliferation accelerating pre-existing malignant changes) is plausible but unproven. Given the lack of long-term safety data, this represents a genuine and uncharacterised risk.
Is melanotan 2 legal?
Melanotan II is not approved for human use by the FDA, EMA, TGA, or any major regulatory agency. It is classified as a WADA prohibited substance (S2 Peptide Hormones). The UK’s MHRA, Australia’s TGA, and European health authorities have issued specific safety warnings against its use. It is sold in unregulated markets, typically labelled “for research purposes only,” and products sourced from internet vendors have documented quality control concerns.
How long does melanotan 2 last in the body?
The plasma half-life of melanotan II is approximately 1 hour. However, the melanogenic (tanning) effects persist much longer — measurable increases in pigmentation have been documented for at least one week after dosing ended in Phase I research, because the melanin deposited in skin cells remains until those cells are naturally shed through epidermal turnover.[1]
What is the difference between melanotan injection and melanotan nasal spray?
Both melanotan injection (subcutaneous) and melanotan nasal spray have been investigated as delivery routes. Subcutaneous injection provides more predictable absorption and higher bioavailability. Intranasal delivery shows detectable bioavailability but with greater variability between subjects. Neither route is approved for human use, and both carry the same safety concerns associated with the compound itself.
Why was melanotan 2 development discontinued?
Clinical development was discontinued primarily due to the unfavourable benefit-risk profile created by non-selective melanocortin receptor activation. The tanning effect could not be separated from nausea, sexual side effects, autonomic disturbances, and dermatological safety concerns. The melanogenic pathway was pursued instead through afamelanotide (more MC1R-selective), while the sexual function pathway was pursued through PT-141 (more MC3R/MC4R-selective). Both selective derivatives ultimately reached regulatory approval, while the non-selective parent compound did not.
References
- Dorr RT, Lines R, Levine N, et al. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sci. 1996;58(20):1777-1784. PubMed
- Hadley ME. Discovery that a melanocortin regulates sexual functions in male and female humans. Peptides. 2005;26(10):1687-1689. PubMed
- Wessells H, Fuciarelli K, Hansen J, et al. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. J Urol. 1998;160(2):389-393. PubMed
- Wessells H, Gralnek D, Dorr R, Hruby VJ, Hadley ME, Levine N. Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction. Urology. 2000;56(4):641-646. PubMed
- Wessells H, Levine N, Hadley ME, Dorr R, Hruby V. Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II. Int J Impot Res. 2000;12 Suppl 4:S74-S79. PubMed
- Habbema L, Halk AB, Neumann M, Bergman W. Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review. Int J Dermatol. 2017;56(10):975-980. PubMed
- Mang R, Krahl D, Assmann T. Dermoscopic changes in melanocytic nevi during use of melanotan II. Hautarzt. 2012;63(11):880-884. PubMed
- Langan EA, Nie Z, Rhodes LE. Melanotropic peptides: more than just ‘Barbie drugs’ and ‘sun-tan jabs’? Br J Dermatol. 2010;163(3):451-455. PubMed
- Peters B, Hadimeri J, Gärskog O, Tiselius C, Ekberg J. Melanotan II: a possible cause of renal infarction: review of the literature and case report. CEN Case Rep. 2020;9(2):159-161. PubMed
- Fani L, Bak S, Delhanty P, van Rossum EFC, van den Akker ELT. The melanocortin-4 receptor as target for obesity treatment: a systematic review of emerging pharmacological therapeutic options. Int J Obes (Lond). 2014;38(2):163-169. PubMed